> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letters
- URL: https://www.fdaweb.com/latest-fda-warning-letters-120/
- Published: 2017-07-10T12:00:00.000Z
- Updated: 2026-09-14T22:33:01.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139083

During ***FDA Webview***’s annual July Fourth break, FDA posted its latest batch of Warning Letters that included one medical product company. It can be accessed by clicking on the link following the letter.

  
**Shandong Analysis and Test Center** — Jinan, Shandong, China (6/22): FDA inspected the firm 1/16-18 and cited significant GMP deviations in its active pharmaceutical ingredient testing. For example, the contract lab analyzes samples of heparin and heparin-related drugs for the presence of over-sulfated chondroitin sulfate using nuclear magnetic resonance spectroscopy, but it failed to routinely establish system suitability when testing samples. FDA also found that the firm’s control unit did not have basic controls to prevent changes to electronically-stored laboratory data. Additionally, the firm failed to provide additional information requested by the agency about certain customers’ test results.  
[https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/ucm565030.htm](https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/ucm565030.htm?ref=fdaweb.com)